UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease

Lees, AJ; Ratziu, V; Tolosa, E; Oertel, WH; (2007) Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J NEUROL NEUROSUR PS , 78 (9) 944 - 948. 10.1136/jnnp.2006.097154. Gold open access

Abstract

Objective: The safety and tolerability of adjunctive tolcapone initiated simultaneously with levodopa was evaluated with a focus on increases in liver transaminase and hepatotoxicity.Methods: 677 levodopa- naive patients with early stage Parkinson's disease ( PD) were randomised to receive placebo or tolcapone 100 mg three times daily, added to standard doses of levodopa plus carbidopa or benserazide.Results: Increases in liver transaminase above the upper limit of normal ( ULN) occurred in 69/ 342 ( 20.2%) and 92/ 335 ( 27.5%) patients in the placebo and tolcapone groups, respectively. Increases >= 3 times the ULN occurred in 4/ 342 ( 1.2%) and 6/ 335 ( 1.8%) patients receiving placebo and tolcapone, respectively ( p = 0.5). Liver transaminase values returned to normal in 65% of placebo and 80% of tolcapone treated patients. No instances of serious hepatotoxicity were seen. Diarrhoea was the most commonly reported AE - 36/ 342 ( 11.0%) placebo v 98/ 335 ( 29.0%) tolcapone - and caused discontinuation in 9.9% of tolcapone treated patients. Overall, study discontinuation due to adverse effects was 2.9% in the placebo group and 17.3% in the tolcapone group.Conclusions: Tolcapone seemed to be safe and was generally well tolerated as an adjunctive treatment in patients starting treatment with carbidopa/ levodopa for symptomatic PD. Mild increases in transaminase levels -, 3 times the ULN - occurred commonly in both placebo and tolcapone treated patients, whereas potentially serious increases of up to >= 3 times the ULN were infrequent.

Type: Article
Title: Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Open access status: An open access publication
DOI: 10.1136/jnnp.2006.097154
Publisher version: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC21178...
Keywords: IMPROVES MOTOR FUNCTION, DOUBLE-BLIND, LEVODOPA, TRIAL, MULTICENTER, DEPRESSION
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: http://discovery.ucl.ac.uk/id/eprint/115967
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item